New studies add weight to link between pre-eclampsia and heart disease

November 01, 2007

Two studies, published together on bmj.com today, add further weight to the theory that pre-eclampsia and cardiovascular diseases may share common causes or mechanisms.

The first study finds that women who have had pre-eclampsia during pregnancy have a more than two fold higher risk of heart disease in later life, while the second shows that women with cardiovascular risk factors that are present years before pregnancy may be predisposed to pre-eclampsia.

Pre-eclampsia is a serious condition where abnormally high blood pressure and other disturbances develop in the second half of pregnancy. It affects about 5% of all first-time pregnancies and is dangerous for both mother and child.

In the first study, researchers in London analysed 25 studies involving over 3 million women to calculate the future health risks of women who have had a pregnancy affected by pre-eclampsia that is likely explained by the association with heart disease.

They found a small increase in overall mortality among women who had had pre-eclampsia. Women with a history of pre-eclampsia also had an almost four fold increased risk of high blood pressure (hypertension) and a two fold increased risk of fatal and non-fatal ischaemic heart disease, stroke, and blood clots (venous thromboembolism) in later life.

They found no increase in risk of any cancer, including breast cancer, suggesting a specific relationship between pre-eclampsia and cardiovascular disease.

The authors explain that, since the risk of a cardiovascular event increases with age, and assuming that the effect of the pre-eclampsia is independent of other risk factors, absolute risk at age 50-59 years would be around 8% without and 17% with a history of pre-eclampsia and at 60-69 years the risk would be 14% without and around 30% for a woman with a history of pre-eclampsia.

This suggests that a woman with pre-eclampsia might become eligible for preventative therapies at an earlier age than would otherwise be the case.

The mechanism underlying this association remains to be defined, but whatever its nature, a history of pre-eclampsia should be considered when evaluating risk of cardiovascular disease in middle aged women, they conclude.

In the second study, researchers in Norway examined whether cardiovascular risk factors assessed before conception predict pre-eclampsia.

3,494 women were included in the analysis. Several cardiovascular risk markers, including blood pressure, cholesterol and blood sugar levels, weight, and body mass index, were recorded before pregnancy.

133 (3.8%) of these women had a pregnancy complicated by pre-eclampsia. After adjusting for factors such as smoking and social status, the odds of pre-eclampsia were seven times greater in women with high pre-pregnant blood pressure, total cholesterol and blood sugar levels compared to women with readings in the normal range.

Furthermore, a family history of high blood pressure, ischaemic heart disease, or diabetes was each associated with a doubling in risk, while overweight and obese women also had a higher risk compared to women of normal weight. Women who used oral contraceptives before pregnancy had half the risk of pre-eclampsia compared to never or previous users.

These results show that unfavourable cardiovascular risk factors that were present years before pregnancy are strong predictors of pre-eclampsia, suggesting that pre-eclampsia and cardiovascular diseases may share a common origin, say the authors.

However, this does not rule out the possibility that the pre-eclamptic process itself may also contribute to subsequent cardiovascular risk, they conclude.

An accompanying editorial says that guidelines for prevention of cardiovascular disease are appropriate for all women, while future research must investigate whether women with previous pre-eclampsia should have their cardiovascular risk markers treated earlier and more aggressively (or both).
-end-


BMJ

Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.